Colossal Biosciences Eyes Massive New Funding Round at $20B to $30B Valuation
Colossal Biosciences is reportedly in talks to raise fresh capital at a valuation between twenty billion and thirty billion dollars.
The de-extinction startup previously achieved a ten point two billion dollar valuation after securing two hundred million dollars in funding.
De-Extinction Startup Builds Diverse Revenue Streams
The company has begun generating revenue in the past year through sales of its conservation technologies.
Colossal has already spun out several ventures including one focused on breaking down plastics and another providing computational biology tools.
One spinout in artificial intelligence for life sciences reached a two billion dollar valuation earlier this year.
These moves show how the core technology extends well beyond bringing back extinct species like the woolly mammoth.
Broader Implications for Biotech and Conservation
The potential artificial womb technology could one day support human fertility treatments once ready next year.
Biodiversity credits represent another long-term revenue path if reintroduced animals thrive in the wild.
Such high valuations highlight growing investor confidence in synthetic biology amid rising climate challenges.
This development could accelerate innovations that help preserve ecosystems and advance medical applications for everyday people.
Overall the talks reflect a booming sector where deep tech meets real world problem solving.
